e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment
Kreuter M., Kropff M., Fischaleck A., Junker K., Gerss J., Heinecke A., Lindermann M., Reinmuth N., Berdel W. E., Mesters R. M., Thomas M.
Source:
Eur Respir J 2009; 33: 1383-1388
Journal Issue:
June
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kreuter M., Kropff M., Fischaleck A., Junker K., Gerss J., Heinecke A., Lindermann M., Reinmuth N., Berdel W. E., Mesters R. M., Thomas M.. Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 2009; 33: 1383-1388
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Different morphological changes in non-small cell lung cancers and their corresponding lymph node metastases after neoadjuvant therapy?
Source: Eur Respir J 2004; 24: Suppl. 48, 479s
Year: 2004
A novel biologic classification of non-small cell lung cancer
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005
Staging and restaging in the era of multimodality treatment
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer
Source: Eur Respir J 2013; 41: 649-655
Year: 2013
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Accuracy of re-mediastinoscopy and fusion PET-CT in the assessment of lymph node (LN) downstaging after induction chemotherapy for N2 non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 602s
Year: 2006
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 269s
Year: 2002
Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm
Source: Eur Respir J 2010; 36: 1355-1361
Year: 2010
Objective measurement of tumor central location can predict nodal involvement in patients with cT1N0M0 non-small cell lung cancer
Source: Virtual Congress 2020 – Screening and early lung cancer
Year: 2020
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Which definition of a central tumour is more predictive of occult mediastinal metastasis in nonsmall cell lung cancer patients with radiological N0 disease?
Source: Eur Respir J, 53 (3) 1801508; 10.1183/13993003.01508-2018
Year: 2019
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Staging of lung cancer
Source: Eur Respir Mon; 2009: 44: 150–168
Year: 2009
Analysis of risk factors for brain metastasis in locally advanced stage non-small cell carcinoma
Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept